Advitech announces positive clinical and pre-clinical results


    QUEBEC CITY, July 3 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) announces today positive results from
its clinical trials on psoriasis, eczema and pre-clinical program on wound


    A double blind, placebo-controlled study has confirmed the efficacy of
Dermylex(R) on mild-to-moderate psoriasis at a daily dosage of 800 mg per day.
During this study, patients took 800 mg per day of Dermylex(R) for a period of
56 days and efficacy was measured by the Dermatology Life Quality Index
(DLQI), Psoriasis Area and Severity Index (PASI) and itching sensation scores
at day 1 and day 56. Results showed a significant increased quality of life
(DLQI) and a reduced PASI and itching sensation scores by day 56 in subjects
taking Dermylex(R)compared to placebo (p(less than)0.05). In summary, daily
administration of 800 mg of Dermylex(R) for 56 days is adequate to improve the
quality of life and decrease disease severity in patients with
mild-to-moderate psoriasis. This study was conducted at the Centre de
Recherche Dematologique du Québec Métropolitain in Quebec City. The detailed
results of this clinical trial will be published in the next edition of
Alternative Medicine Review, a peer reviewed journal.


    An open label study conducted by Innovaderm Research, in Montreal, has
generated significant data suggesting that XP-312, a product developed by
Advitech, has utility in the treatment of eczema. Patients were asked to take
800 mg/day of XP-312 (oral form) for a period of 90 days. Eczema Area and
Severity Index (EASI) and the Dermatology Life Quality Index (DLQI) scores
were evaluated following 30, 60 and 90 days. Following 90 days of treatment,
66% of patients have experienced a significant improvement on these scores,
without side effects. Furthermore, 67% of patients taking XP-312 experienced
an improvement in the quality of life index after 90 days. More than 50% of
the patients showed an improved condition after only 30 days of treatment.
    Both clinical studies (Psoriasis and Eczema) were approved by Health
Canada. Advitech is currently exploring commercial opportunities for the
eczema product.
    "These results on psoriasis and eczema applications further validate our
unique proprietary technological platform for immune-related skin disorders"
said Renaud Beauchesne, President and CEO of Advitech.


    Recent additional data generated in the Wound Healing pre-clinical
program confirm the unique properties of the IM-fraction technological
platform. New data confirmed an increase in the metabolic activity of human
fibroblasts and a reduction of collagen contraction while both reducing the
presence of stress fibres and excessive number of fibroblasts, this suggesting
a unique property of the IM-fraction technological platform to potentially
reduce excessive scaring. "These latter characteristics are very important for
the proper remodelling in wound repair and their simultaneous action in one
single product would be a unique advantage of the Advitech's IM-Fraction
technological platform" has indicated Dr Charles Doillon M.D, PhD who is
piloting this program.
    For the wound healing application, Advitech has a R&D program targeting a
more in depth characterisation of specific fractions and a toxicology program
with additional in-vitro and in-vivo studies. This significant program will be
initiated this summer and should be completed by year end, or early 2009. As
previously stated, the Company intends to seek a strategic partner to further
develop the wound healing applications.


    Dermylex(R), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(R) for that type of psoriasis. Dermylex(R) is currently available in
Canada and the U.S. (as BioDerm, Dermalyx(R)), as well as in France and
Belgium (as Psopax(R)).


    The general consensus is that Atopic Dermatitis (Eczema) is an
immune-mediated skin disease characterized by a predominance of IL-4 leading
to IgE production resulting in inflammation. Atopic dermatitis, or eczema, is
a chronic skin disorder characterized by pruritus, dry skin, and excoriation,
which may be localized to a few patches or involve large portions of the body.
It is a common disease affecting approximately 6% of the general population,
particularly children. In the United States alone, it is estimated that more
than 15 million individuals are afflicted with this disorder.


    According to Epsicom Business Intelligence Ltd., the global wound care
market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factors
based applications for wound healing represent more than 5% of the market,
with an impressive 27% growth rate.


    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
mild-to-moderate psoriasis.
    Advitech has developed a research program for new applications related to
wound healing. This development is derived from both its XP-828L and IM
technological platforms.

    This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF

For further information:

For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,; Serge Comeau, Investor's relations, (514) 862-4160,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890